Enochian Biosciences, Inc. (ENOB): Price and Financial Metrics
GET POWR RATINGS... FREE!
ENOB Stock Price Chart Interactive Chart >
ENOB Price/Volume Stats
| Current price | $6.26 | 52-week high | $13.78 |
| Prev. close | $6.03 | 52-week low | $3.70 |
| Day low | $5.96 | Volume | 146,600 |
| Day high | $6.39 | Avg. volume | 214,707 |
| 50-day MA | $7.41 | Dividend yield | N/A |
| 200-day MA | $7.58 | Market Cap | 331.47M |
Enochian Biosciences, Inc. (ENOB) Company Bio
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.
Latest ENOB News From Around the Web
Below are the latest news stories about Enochian Biosciences Inc that investors may wish to consider to help them evaluate ENOB as an investment opportunity.
Enochian BioSciences, Inc.: Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid TumorsLOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today |
Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid TumorsLOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, Inventor and Co-Founder of Enochian BioSciences, and Founder and Director of Seraph Research Institute (SRI), presented new data and announced a partnership between Enochian and Dr. Anahid Jewett, a leader in tumor immunology and cell and gene therapy, on pancreatic cancer, as well as a combined effort with SRI and Enochian on Glioblastoma. |
Vanguard Group Inc. Sells 52,662 Shares of Enochian Biosciences, Inc. (NASDAQ:ENOB)Vanguard Group Inc. reduced its stake in Enochian Biosciences, Inc. (NASDAQ:ENOB) by 16.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 273,656 shares of the companys stock after selling 52,662 shares during the period. Vanguard Group Inc.s holdings in Enochian Biosciences were worth [] |
Enochian Biosciences (NASDAQ:ENOB) Shares Up 6.6%Enochian Biosciences, Inc. (NASDAQ:ENOB)s share price shot up 6.6% on Wednesday . The stock traded as high as $10.00 and last traded at $10.00. 1,000 shares were traded during mid-day trading, a decline of 99% from the average session volume of 198,485 shares. The stock had previously closed at $9.38. The company has a debt-to-equity [] |
Bank of New York Mellon Corp Lowers Stock Position in Enochian Biosciences, Inc. (NASDAQ:ENOB)Bank of New York Mellon Corp lowered its position in Enochian Biosciences, Inc. (NASDAQ:ENOB) by 78.1% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 11,377 shares of the companys stock after selling 40,638 shares during the period. Bank of New York Mellon Corps holdings in Enochian Biosciences were worth $57,000 as of its most [] |
ENOB Price Returns
| 1-mo | -17.63% |
| 3-mo | N/A |
| 6-mo | -40.55% |
| 1-year | 63.45% |
| 3-year | -2.34% |
| 5-year | N/A |
| YTD | -14.13% |
| 2021 | 147.12% |
| 2020 | -41.24% |
| 2019 | -28.29% |
| 2018 | 47.37% |
| 2017 | 216.67% |
Loading social stream, please wait...